top of page

The Space Between Manufacturing & Market Article # 5: Is Quality Enough? Why High-Quality Devices Still Struggle in the Market

Oct 1
4 min read

In regulated industries like medical device manufacturing, quality is often viewed as the foundation of everything. Entire systems are built around it. Procedures, audits, validations, documentation controls, risk management activities, inspections, and training programs all exist to support one central goal: producing safe, reliable, and consistent products. And rightfully so.


Quality matters enormously in healthcare. Patients depend on it. Providers expect it. Regulators require it. Without strong quality systems, products can fail, risks increase, and organizations can quickly lose trust. But there is another side to the conversation that is not always discussed openly enough. Sometimes, even high-quality products still struggle in the market.


At first glance, that can feel confusing. Many people naturally assume that if a product is well-made, compliant, clinically effective, and supported by strong manufacturing processes, success should follow automatically. In reality, healthcare markets are much more complicated than that. Quality is critical, but quality alone is not always enough to guarantee adoption, growth, or long-term commercial success. This is one of the realities that exists in the space between manufacturing and market.


A device may leave the manufacturing floor with excellent quality metrics, strong documentation, successful validations, and fully compliant processes behind it. Internally, teams may view the project as a success because everything functioned exactly as intended from an operational standpoint. But once that product enters the broader healthcare ecosystem, entirely different challenges begin to appear.


Healthcare organizations may already be loyal to competing products. Physicians may resist changing established workflows. Hospitals may not have the budget to support implementation. Reimbursement limitations may create financial uncertainty. Sales teams may struggle to communicate the product’s value clearly enough to decision-makers. Training requirements may seem too complex. Supply chain pressures may impact availability. In some cases, the market may simply not be ready for the product yet.


None of those issues necessarily reflect poor quality. That distinction is important. Sometimes organizations unintentionally view market struggles as operational failures when the reality is much broader than that. Manufacturing teams can do everything correctly and still watch a product face commercial resistance for reasons outside of manufacturing itself. This is where the definition of “success” can start to differ across departments.


Quality and manufacturing teams often measure success through compliance, consistency, traceability, process control, and product reliability. Commercial teams may focus on adoption rates, market penetration, customer demand, and revenue performance. Leadership teams may focus on long-term scalability and profitability. Clinicians may focus on usability and workflow impact. Providers may focus on reimbursement and financial sustainability. Every group may be evaluating the same product through a completely different lens. That disconnect can create frustration if organizations are not aligned early in development.


A product can absolutely be considered “high quality” while simultaneously struggling commercially. Those two realities can exist at the same time, even though they may appear contradictory from the outside. In many ways, this highlights how interconnected healthcare innovation really is. Product quality is only one piece of a much larger system involving regulation, reimbursement, provider adoption, operational integration, clinical acceptance, financial viability, and patient accessibility.


When one part of that system is weak, even excellent products can struggle to gain momentum. This also helps explain why some organizations now place greater emphasis on cross-functional collaboration much earlier in product development. Manufacturing, quality, regulatory, clinical, reimbursement, and commercial teams are increasingly expected to work together rather than operate in isolated silos. The earlier those conversations happen, the easier it becomes to identify risks that may not be visible from only one department’s perspective.


A product may technically be “ready,” but the market surrounding it may not be. That reality does not diminish the importance of quality. If anything, it reinforces how essential quality truly is. High quality remains the baseline expectation in healthcare, not the differentiator by itself. Organizations are expected to deliver safe, compliant, and reliable products before they can even begin competing in the market.


The challenge is that market success often requires much more than meeting that baseline alone. It requires alignment between innovation, manufacturing, reimbursement strategy, operational practicality, customer education, financial incentives, and real-world adoption behaviors. Healthcare systems are complex, and success within them is rarely driven by a single factor.


That complexity is part of what makes healthcare commercialization so challenging to navigate. A strong quality system may help a product reach the market successfully, but it does not automatically guarantee the market will fully embrace it once it gets there. And sometimes, understanding that distinction early may be one of the most important lessons an organization can learn.



Katie Casteel works in a regulated medical device environment and is currently pursuing a PhD in Information Technology with a cyber engineering focus. Her research interests include IT governance, cybersecurity, and organizational risk management.


This article is part of The Space Between Manufacturing & Market series, which explores the gap between building compliant, high-quality products and achieving real-world success in the market.

 
 
 

Comments

bottom of page